{"id":"W2780073276","doi":"10.1200/jco.2017.35.15_suppl.e20504","title":"Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Adverse effect; Discontinuation; Oncology; Phases of clinical research; Gastroenterology; Cancer; Clinical trial; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002669114,0.0005499067,0.0008541812,0.000265025,0.0001529944,0.0006644299,0.0006278603,0.0005221604,0.001476057],"category_scores_gemma":[0.001170542,0.0002556552,0.000673678,0.0003012171,0.0002422139,0.0004498723,0.0001672276,0.0009725588,0.0003672057],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007827235,"about_ca_system_score_gemma":0.0007094773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007561856,"about_ca_topic_score_gemma":0.002378144,"domain_scores_codex":[0.999468,0.0002427096,0.00003807724,0.00005633691,0.0001415915,0.00005328848],"domain_scores_gemma":[0.9991732,0.0001818171,0.0003349778,0.0000770283,0.00008761759,0.0001452833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1543247,0.02225934,0.09516148,0.002814034,0.006055082,0.001074356,0.0004352576,0.004655059,0.1979867,0.0003026747,0.01956006,0.4953712],"study_design_scores_gemma":[0.1377622,0.3438627,0.3947178,0.0002816996,0.006464752,0.007808948,0.0001611619,0.005407734,0.05997753,0.0004466879,0.04297282,0.0001359804],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981079,0.01039177,0.0009513446,0.0003731633,0.00005526526,0.0007396357,0.003846946,0.0001287353,0.002434111],"genre_scores_gemma":[0.9829379,0.003734637,0.001942048,0.0007028998,0.00007388682,0.0003755554,0.008933816,0.00003016575,0.001269078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002669114,"threshold_uncertainty_score":0.01411575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1417976650562891,"score_gpt":0.5247077997151413,"score_spread":0.3829101346588522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}